Golden
Rheostat Therapeutics

Rheostat Therapeutics

Rheostat, located at LabCentral, Cambridge, Massachusetts is a biotech company developing treatments for neurodegenerative diseases by targeting mitophagy and autophagy pathways.

Rheostat is a biotechnology company developing treatments for neurodegenerative disease by modulation of mitophagy and autophagy that is headquartered in Cambridge, Massachusetts and was founded in 2018 by Tim Harris, Wade Harper, Bert Vallee, and Natalie Vallee. 



Rheostat is focusing on molecular pathways involved in clearance of toxic components such as damaged organelles or aggregated proteins because mutations in these pathways cause many neurodegenerative diseases associated with cognitive impairment. Rheostat aims to use knowledge about these clearance pathways to find and develop small molecules that can restore cellular balance for the treatment of neurodegenerative and rare diseases. 

Funding

Series A

On November 26, 2018 Rheostat Therapeutics completed their series A funding round with $23 million in funding from MRL Ventures Fund (lead investor), AbbVie Biotech Ventures, SV Health Investors, Dementia Discovery Fund, Amgen Ventures, Alexandria Venture Investments, and the Dementia Discovery Fund. 

Timeline

People

Name
Role
Related Golden topics

Christophe J. Echeverri

Interim Head of Operations



Darby R. Schmidt

Senior Director, Head of Chemistry



J. Stefan Kaczmarek

Scientific Director



Joshua Resnick

Chair and CEO



Magdalene Moran

Principle Investigator



Nathaniel Tyler Blair

Associate Director of Biology



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References